U.S. Markets closed

S&P Futures
3,739.75
-4.50(-0.12%)
Dow Futures
30,190.00
+1.00(+0.00%)
Nasdaq Futures
13,073.00
-32.50(-0.25%)

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

21.54-0.15 (-0.69%)

At close: 4:00PM EST

21.55 +0.01 (0.05%)
After hours: 6:23PM EST

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	21.69
Open	21.48
Bid	20.03 x 1200
Ask	21.55 x 900
Day's Range	20.84 - 22.09
52 Week Range	11.98 - 23.02
Volume	1,457,184
Avg. Volume	1,298,004

Market Cap	3.428B
Beta (5Y Monthly)	1.25
PE Ratio (TTM)	N/A
EPS (TTM)	-0.46
Earnings Date	Feb 10, 2021 - Feb 15, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	21.36

All

Research Reports

Zacks
BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
Zacks
Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA
Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.
- Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer
  Business Wire
- Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
  GlobeNewswire
Zacks
Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review
Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.